Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OxARO
- Development stage
- Preclinical
- Lead developer
- SafeRx Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OxARO is a fixed-dose combination small molecule drug being developed by SafeRx Pharmaceuticals to address moderate-to-severe pain and opioid use disorder while mitigating the risks of concurrent alcohol consumption. It combines oxycodone hydrochloride, a mu-opioid receptor (MOR) agonist, with disulfiram, an aldehyde dehydrogenase (ALDH) inhibitor. This combination is part of the Alcohol-Resistant Opioid (ARO) platform, designed to trigger an unpleasant physiological reaction if alcohol is consumed, thereby deterring the dangerous co-ingestion of opioids and alcohol. SafeRx Pharmaceuticals is pursuing FDA approval through the accelerated 505(b)(2) regulatory pathway, leveraging existing safety and efficacy data for the individual components.
- Brand names
- OxARO
- Other names
- OxARO IR
02
Targets
ALDH1A1 (Aldehyde dehydrogenase 1 family member A1)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on OxARO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OxARO.